Overview

Immune Modulation Therapy for Pompe Disease

Status:
Unknown status

Trial end date:
2020-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers after treatment with immune modulation therapy in patients of Pompe disease.

Phase:

Phase 4

Details

Lead Sponsor:

National Taiwan University Hospital

Treatments:

Antibodies
Bortezomib
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Methotrexate
Rho(D) Immune Globulin
Rituximab